Sökning: onr:"swepub:oai:gup.ub.gu.se/175106" >
Treatment of Anemia...
Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure
-
- Swedberg, Karl, 1944 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
Young, J. B. (författare)
-
Anand, I. S. (författare)
-
visa fler...
-
Cheng, S. (författare)
-
Desai, A. S. (författare)
-
Diaz, R. (författare)
-
Maggioni, A. P. (författare)
-
McMurray, J. J. (författare)
-
O'Connor, C. (författare)
-
Pfeffer, M. A. (författare)
-
Solomon, S. D. (författare)
-
Sun, Y. (författare)
-
Tendera, M. (författare)
-
van Veldhuisen, D. J. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2013
- 2013
- Engelska.
-
Ingår i: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 368:13, s. 1210-1219
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia. Methods In this randomized, double-blind trial, we assigned 2278 patients with systolic heart failure and mild-to-moderate anemia (hemoglobin level, 9.0 to 12.0 g per deciliter) to receive either darbepoetin alfa (to achieve a hemoglobin target of 13 g per deciliter) or placebo. The primary outcome was a composite of death from any cause or hospitalization for worsening heart failure. Results The primary outcome occurred in 576 of 1136 patients (50.7%) in the darbepoetin alfa group and 565 of 1142 patients (49.5%) in the placebo group (hazard ratio in the darbepoetin alfa group, 1.01; 95% confidence interval, 0.90 to 1.13; P=0.87). There was no significant between-group difference in any of the secondary outcomes. The neutral effect of darbepoetin alfa was consistent across all prespecified subgroups. Fatal or nonfatal stroke occurred in 42 patients (3.7%) in the darbepoetin alfa group and 31 patients (2.7%) in the placebo group (P=0.23). Thromboembolic adverse events were reported in 153 patients (13.5%) in the darbepoetin alfa group and 114 patients (10.0%) in the placebo group (P=0.01). Cancer-related adverse events were similar in the two study groups. Conclusions Treatment with darbepoetin alfa did not improve clinical outcomes in patients with systolic heart failure and mild-to-moderate anemia. Our findings do not support the use of darbepoetin alfa in these patients. (Funded by Amgen; RED-HF ClinicalTrials.gov number, NCT00358215 .).
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Nyckelord
- chronic heart failure
- Aged
- Anemia/drug therapy
- Anemia/etiology
- Double-Blind Method
- Erythropoietin/adverse effects
- Erythropoietin/analogs & derivatives
- Erythropoietin/therapeutic use
- Female
- Heart Failure
- Systolic/complications
- Heart Failure
- Systolic/drug therapy
- Heart Failure
- Systolic/mortality
- Hematinics/adverse effects
- Hematinics/therapeutic use
- Hemoglobins/analysis
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Proportional Hazards Models
- Shock
- Septic/etiology
- Stroke/etiology
- Thromboembolism/etiology
- Treatment Failure
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Swedberg, Karl, ...
-
Young, J. B.
-
Anand, I. S.
-
Cheng, S.
-
Desai, A. S.
-
Diaz, R.
-
visa fler...
-
Maggioni, A. P.
-
McMurray, J. J.
-
O'Connor, C.
-
Pfeffer, M. A.
-
Solomon, S. D.
-
Sun, Y.
-
Tendera, M.
-
van Veldhuisen, ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
New England Jour ...
- Av lärosätet
-
Göteborgs universitet